On Tuesday, the Helsinki stock exchange finally ended in decline and the index fell below 10,000 points. The OMXH general index ended with a decrease of 0.4 percent to 9,990.09 points.
A health technology company Nightingale Health reports on two official approvals. The company has received another regulatory approval from the Health Science Authority of Singapore (HSA), which regulates medical devices and other healthcare products. In addition, the company’s blood analysis technology is UKCA-marked in accordance with the requirements for medical devices in Great Britain. The company’s share price ended on Tuesday with a strong 15.4 percent increase to 3.15 euros.
The list of the most traded shares ended up rising, among other things UPM (+1,1 %), Stora Enso R (+1.1%) and Kone (+0.5%). Instead, they ended up with, among other things Nordea (-1.6%) and Sampo (-0,7 %).
Revenue through acquisitions
Pharmaceutical technology company Revenue said its subsidiary Icare Finland a Dutch software company to buy Thirona Retina B.V:n. Last year, Icare Finland made a minority investment of EUR 1.9 million in Thirona Retina. In accordance with the agreement made in connection with that, Icare Finland has now bought the rest of Thirona Retina’s stock for approximately EUR 4.8 million.
Revenio’s price ended with a decrease of 1.1 percent to 31.66 euros.
Construction company YIT said that he had signed an agreement with the city of Lappeenranta on the implementation of an indoor gym suitable for sports and events. The value of the contract is approximately EUR 14 million and it will be recorded in YIT’s order book for the third quarter.
YIT’s price ended with a 0.7 percent increase to 2.46 euros.
Fuel company In this said that it is expanding the logistics solutions for liquefied recycled raw materials, such as liquefied waste plastic and pyrolysis oil obtained from discarded tires, at the Porvoo refinery.
Neste’s share price ended up down 1.6 percent to 19.90 euros.
Tuesday’s results publishers
On Tuesday, four companies published their results for the first half of the year, and it was the alcoholic beverage brand house’s turn Anoraan IT service company Networksa private equity firm Talkative and a software development company Witted Megacorp.
Anora’s profitability improved, but the import of mild wines to grocery stores in Finland had a downward effect on sales, as expected. The company’s turnover fell to 177.1 million euros in April-June from 182.7 million. Adjusted EBITDA improved to 15.2 million euros from 13 million in the comparison period. EBITDA, however, fell short of analysts’ forecasts.
Anora’s share price ended with a 2.3 percent decrease to 4.33 euros.
Netum’s operating profit and turnover increased. The turnover rose to 11.3 million euros and the operating result was profitable to 0.1 million euros from the operating loss of 0.4 million euros in the comparison period.
Netum’s share ended with a 2.0 percent increase to 3.06 euros.
Taaleri’s operating profit shrank to 4.4 million euros from 17.8 million euros, when the analysis house Inderes the forecast was 3.9 million euros. Turnover shrank to 11.9 million euros from 26.3 million euros in the comparison period a year ago. Taaleri’s investment income swings the turnover briskly on a quarterly basis.
The exchange rate of the taaler ended with a decrease of 2.9 percent to 8.34 euros.
Witted Megacorp’s turnover decreased by 15.8 percent from the comparison period and was 13.7 million euros, but the ebita result turned profitable to 0.4 million euros from the ebita result of -0.4 million euros in the comparison period.
Witted’s share price ended with a 9.8 percent increase to 1.80 euros.
Recommendation changes
Inderes raised Talenom’s investment recommendation to buy, previous add. The target price of the share decreased to 5.60 euros from 6.00 euros.
Inderes raised the target price of Springvest shares to 7.80 euros from 6.20 euros. The recommendation drops to the level of decrease, the previous one increases.
Inderes raised the target price of Ecoup’s share to EUR 2.00 from EUR 1.80. The recommendation is still to reduce.